Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes

Autores
Belli, Carolina Bárbara; Bestach, Yesica Soledad; Kornblihtt, Laura Inés; Larripa, Irene Beatriz
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematological diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical practice helping to define subgroups of MDS patients who share similarities in the course of the disease. There are recurring aberrations affecting chromosomes 5, 7, 8, and 20. While all of them do not suggest a therapeutic approach, their presence has been considered as a risk indicator since the original international prognostic scoring system (IPSS) was published. The most recent cytogenetic stratifications tried to find the prognostic significance of less frequent alterations which have been longer included in the intermediate group. Moreover, monitoring of karyotype changes is suggested to evaluate cytogenetic response to treatments and the acquisition of new aberrations associated to an unfavorable outcome. This review focuses on different cytogenetic risk stratifications that have been published during the past twenty years and the molecular background of the most relevant chromosomal findings.
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Kornblihtt, Laura Inés. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martin; Argentina
Fil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Materia
Síndromes Mielodiasplasicos
Citogenética
Pronostico
Cariotipo
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/78643

id CONICETDig_dbe8259e77288f6f509055007bd22946
oai_identifier_str oai:ri.conicet.gov.ar:11336/78643
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Prognostic Implications of Cytogenetic Features in Myelodysplastic SyndromesBelli, Carolina BárbaraBestach, Yesica SoledadKornblihtt, Laura InésLarripa, Irene BeatrizSíndromes MielodiasplasicosCitogenéticaPronosticoCariotipohttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematological diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical practice helping to define subgroups of MDS patients who share similarities in the course of the disease. There are recurring aberrations affecting chromosomes 5, 7, 8, and 20. While all of them do not suggest a therapeutic approach, their presence has been considered as a risk indicator since the original international prognostic scoring system (IPSS) was published. The most recent cytogenetic stratifications tried to find the prognostic significance of less frequent alterations which have been longer included in the intermediate group. Moreover, monitoring of karyotype changes is suggested to evaluate cytogenetic response to treatments and the acquisition of new aberrations associated to an unfavorable outcome. This review focuses on different cytogenetic risk stratifications that have been published during the past twenty years and the molecular background of the most relevant chromosomal findings.Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Kornblihtt, Laura Inés. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martin; ArgentinaFil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaLondon Touch Briefing2013-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/78643Belli, Carolina Bárbara; Bestach, Yesica Soledad; Kornblihtt, Laura Inés; Larripa, Irene Beatriz; Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes; London Touch Briefing; Oncology & Hematology Review (US); 9; 1; 1-2013; 60-672052-3815CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.17925/OHR.2013.09.1.60info:eu-repo/semantics/altIdentifier/url/https://touchoncology.com/prognostic-implications-of-cytogenetic-features-in-myelodysplastic-syndromes/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:39:22Zoai:ri.conicet.gov.ar:11336/78643instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:39:22.672CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
title Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
spellingShingle Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
Belli, Carolina Bárbara
Síndromes Mielodiasplasicos
Citogenética
Pronostico
Cariotipo
title_short Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
title_full Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
title_fullStr Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
title_full_unstemmed Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
title_sort Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes
dc.creator.none.fl_str_mv Belli, Carolina Bárbara
Bestach, Yesica Soledad
Kornblihtt, Laura Inés
Larripa, Irene Beatriz
author Belli, Carolina Bárbara
author_facet Belli, Carolina Bárbara
Bestach, Yesica Soledad
Kornblihtt, Laura Inés
Larripa, Irene Beatriz
author_role author
author2 Bestach, Yesica Soledad
Kornblihtt, Laura Inés
Larripa, Irene Beatriz
author2_role author
author
author
dc.subject.none.fl_str_mv Síndromes Mielodiasplasicos
Citogenética
Pronostico
Cariotipo
topic Síndromes Mielodiasplasicos
Citogenética
Pronostico
Cariotipo
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematological diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical practice helping to define subgroups of MDS patients who share similarities in the course of the disease. There are recurring aberrations affecting chromosomes 5, 7, 8, and 20. While all of them do not suggest a therapeutic approach, their presence has been considered as a risk indicator since the original international prognostic scoring system (IPSS) was published. The most recent cytogenetic stratifications tried to find the prognostic significance of less frequent alterations which have been longer included in the intermediate group. Moreover, monitoring of karyotype changes is suggested to evaluate cytogenetic response to treatments and the acquisition of new aberrations associated to an unfavorable outcome. This review focuses on different cytogenetic risk stratifications that have been published during the past twenty years and the molecular background of the most relevant chromosomal findings.
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Kornblihtt, Laura Inés. Provincia de Buenos Aires. Hospital Interzonal General de Agudos Gral. San Martin; Argentina
Fil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
description Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematological diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical practice helping to define subgroups of MDS patients who share similarities in the course of the disease. There are recurring aberrations affecting chromosomes 5, 7, 8, and 20. While all of them do not suggest a therapeutic approach, their presence has been considered as a risk indicator since the original international prognostic scoring system (IPSS) was published. The most recent cytogenetic stratifications tried to find the prognostic significance of less frequent alterations which have been longer included in the intermediate group. Moreover, monitoring of karyotype changes is suggested to evaluate cytogenetic response to treatments and the acquisition of new aberrations associated to an unfavorable outcome. This review focuses on different cytogenetic risk stratifications that have been published during the past twenty years and the molecular background of the most relevant chromosomal findings.
publishDate 2013
dc.date.none.fl_str_mv 2013-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/78643
Belli, Carolina Bárbara; Bestach, Yesica Soledad; Kornblihtt, Laura Inés; Larripa, Irene Beatriz; Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes; London Touch Briefing; Oncology & Hematology Review (US); 9; 1; 1-2013; 60-67
2052-3815
CONICET Digital
CONICET
url http://hdl.handle.net/11336/78643
identifier_str_mv Belli, Carolina Bárbara; Bestach, Yesica Soledad; Kornblihtt, Laura Inés; Larripa, Irene Beatriz; Prognostic Implications of Cytogenetic Features in Myelodysplastic Syndromes; London Touch Briefing; Oncology & Hematology Review (US); 9; 1; 1-2013; 60-67
2052-3815
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.17925/OHR.2013.09.1.60
info:eu-repo/semantics/altIdentifier/url/https://touchoncology.com/prognostic-implications-of-cytogenetic-features-in-myelodysplastic-syndromes/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv London Touch Briefing
publisher.none.fl_str_mv London Touch Briefing
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083510424567808
score 13.22299